Pacira BioSciences, Inc.
NASDAQ:PCRX · NASDAQ Global Select
-$0.18 today
Vol 0.76M · Avg 0.57M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PCRX · Revenue to Net Income
Key Ratios
Analysis
$734.9M of revenue converted into $5.1M of net income for the selected period. Gross margin is 79.3% and net margin is 0.7%, showing how much revenue survives after costs and taxes. EPS is $0.12, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M +3.6% | $701.0M +3.9% | $675.0M +1.2% | $666.8M +23.1% | $541.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $149.7M -12.1% | $170.4M -7.7% | $184.7M -7.3% | $199.3M +42.1% | $140.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $576.7M +8.7% | $530.5M +8.2% | $490.3M +4.9% | $467.5M +16.5% | $401.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 79.4% +3.7pp | 75.7% +3.0pp | 72.6% +2.5pp | 70.1% -4.0pp | 74.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $117.3M +43.8% | $81.6M +7.0% | $76.3M -10.1% | $84.8M +52.7% | $55.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $368.8M +25.4% | $294.1M +9.2% | $269.4M +5.9% | $254.5M +27.7% | $199.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $543.4M -10.0% | $603.9M +50.0% | $402.6M -1.2% | $407.5M +30.9% | $311.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $91.0M +15.5% | $78.8M +4.2% | $75.6M -17.4% | $91.5M +220.5% | $28.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $122.5M +320.7% | $29.1M -81.2% | $154.6M +10.1% | $140.4M +23.2% | $113.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 16.9% +12.7pp | 4.2% -18.7pp | 22.9% +1.9pp | 21.1% +0.0pp | 21.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $33.3M +145.4% | -$73.4M -183.7% | $87.7M +46.1% | $60.0M -33.3% | $89.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 4.6% +15.1pp | -10.5% -23.5pp | 13.0% +4.0pp | 9.0% -7.6pp | 16.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $22.7M +15.5% | $19.7M +72.0% | $11.4M +152.0% | $4.5M +406.9% | $896.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $14.6M -11.8% | $16.6M -4.3% | $17.3M -51.3% | $35.6M +22.7% | $29.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$16.4M -260.0% | $10.3M +139.5% | -$26.0M +44.4% | -$46.7M -39.4% | -$33.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $16.9M +126.7% | -$63.1M -202.3% | $61.7M +363.8% | $13.3M -76.4% | $56.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 2.3% +11.3pp | -9.0% -18.1pp | 9.1% +7.1pp | 2.0% -8.4pp | 10.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $9.8M -73.0% | $36.5M +84.6% | $19.7M +857.4% | -$2.6M -118.1% | $14.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | $7.0M +107.1% | -$99.6M -337.3% | $42.0M +163.7% | $15.9M -62.1% | $42.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | 1.0% +15.2pp | -14.2% -20.4pp | 6.2% +3.8pp | 2.4% -5.4pp | 7.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +107.4% | -$2 -336.3% | $1 +160.0% | $0 -63.2% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +107.4% | -$2 -341.6% | $1 +161.8% | $0 -63.0% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $44.6M -3.6% | $46.2M +0.0% | $46.2M +1.5% | $45.5M +2.8% | $44.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $45.0M -2.6% | $46.2M -11.0% | $52.0M +11.7% | $46.5M +2.0% | $45.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.88B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.58B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.07B
Cronos Group Inc.
NASDAQ:CRON
$991.06M
Xencor, Inc.
NASDAQ:XNCR
$938.88M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$855.87M
Oculis Holding AG
NASDAQ:OCS
$629.04M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$607.61M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PCRX generate?
Pacira BioSciences, Inc. (PCRX) reported $726.41M of revenue in fiscal 2025.
Is PCRX profitable?
Pacira BioSciences, Inc. (PCRX) reported $7.03M of net income, with a net margin of 1.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.